Overview

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

Status:
Enrolling by invitation

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

This study will test the effectiveness of lisdexamfetamine medication as a treatment for loss-of-control eating and weight following bariatric surgery. This is a controlled test of whether, amongst non-responders to acute treatments, lisdexamfetamine medication results in superior outcomes compared with placebo.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Yale University

Collaborator:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Treatments:

Lisdexamfetamine Dimesylate